Prescription drug import amendment divides Senate Democrats

NewsGuard 100/100 Score
The Senate is battling over a proposed amendment that would allow prescription drugs to be imported from other countries where prices are lower.

"Drugmakers intensified their lobbying push Monday against a popular proposal to allow Americans to buy cheaper drugs from other countries, one of several heated disputes that have bogged down negotiations over a heath-care reform bill," The Washington Post reports. The dispute complicated Senate Democrats' efforts to rally 60 pass health reform legislation before Christmas and also "poses a particularly difficult political challenge for President Obama, who co-sponsored a similar bill when he was in Congress and who included funding for the idea in his first budget."

"The amendment, sponsored by Sen. Byron L. Dorgan (D-N.D.), would allow pharmacies and wholesalers to import U.S.-approved medication from Canada, Europe, Australia, New Zealand and Japan, where drug costs are far lower because of price controls. The measure has attracted bipartisan support from lawmakers, including Sens. Olympia J. Snowe (R-Maine) and John McCain (R-Ariz.)." The pharmaceutical industry, however, "has responded with a fierce lobbying campaign aimed at killing the proposal, focusing on Democratic senators from states with large drug and research sectors." (Eggen, 12/15).

NPR: "The Congressional Budget Office has estimated there could be more than $100 billion in savings to U.S. prescription drug buyers over the next decade — $20 billion of which would be for the federal government — if cheaper prescription drugs from abroad were allowed to compete in the U.S. market. But opponents question the safety of the drugs. Food and Drug Administration Commissioner Margaret Hamburg wrote several senators saying she commends the efforts Dorgan has made to reduce risks associated with importing prescription drugs. Still, she concluded his measure has too many unresolved safety issues" (Welna, 12/14).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
When it comes to ketamine, Meta’s posting policy is no party to decipher